Lightnews — Scholar-powered news

Reposted by ALK Positive Lung Cancer UK

All You Need is Lungs @allyouneedislungs.bsky.social · 1d

It’s a pinch me moment! All You Need Is Lungs is a finalist tonight at the UK Social Media Awards for Best Charity/Non-Profit Campaign 🎉

Our little team is heading there with some of the amazing voices behind this #LungCancer awareness campaign & thinking of those who are no longer with us.

#LCSM

2 5

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 1d

Today’s NICE decision marks a big step forward for people newly diagnosed with ALK-positive #lungcancer.

Our full statement explains what it means in practice - and why we’ll keep pushing for earlier testing and access.

🔗 www.alkpositive.org.uk/_files/ugd/3...

💙 #LCSM

4

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 2d

‼️ BIG NEWS for ALK+!

NICE has today recommended lorlatinib (Lorbrena) as the first treatment for people in England & Wales newly diagnosed with advanced ALK+ #lungcancer.

Access to the best option from day one matters - this is real progress for people newly diagnosed & starting treatment.

#LCSM

1 4

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 3d

For ALK+ lung cancer, this helps explain why immunotherapy hasn’t yet delivered the same benefit we see in other cancers. Research like this is so key for finding what could change that.

1

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 3d

“9 yrs since my #lungcancer diagnosis” - Debra Montague, ALK+ UK Chair & Founder.

3× longer than the life expectancy I was given. Grateful for every ‘extra year’ & everything it brings: family, friends, advocacy, travel, music & memories. Still saying yes to life & excited for what’s next. 💙 #LCSM

4

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 4d

Prof Sanjay Popat shared an encouraging outlook on ALK+ #lungcancer treatments at our conference last weekend.

Huge thanks to him and to all our experts - we couldn’t make this conference happen every year without you. It’s so important that our community stays informed & empowered. 💙 #LCSM

1 9

Reposted by ALK Positive Lung Cancer UK

Cancer52 @cancer52org.bsky.social · 8d

Busy time at #Lab25, connecting with policy makers and member charities.
With the National Cancer Plan in the final stages of development, it’s a vital time to collaborate to improve outcomes for people affected by rare & less common cancers.

1 2

Reposted by ALK Positive Lung Cancer UK

Patient Information Forum @pifonline.bsky.social · 7d

1/2 - Did you know that half of UK adults struggle to access trusted health information? And that up to 1 million people cannot speak English well or at all?

At PIF, we believe everyone should have access to health information they can understand.

#HealthLiteracyMonth
#HealthLiteracy

1 1 2

Reposted by ALK Positive Lung Cancer UK

The King's Fund @thekingsfund.bsky.social · 4d

This week, Right Reverend and Right Honourable Dame Sarah Mullally DBE was announced as the new Archbishop of Canterbury.

Earlier this year she joined us on our podcast to talk about faith, hope and health inequalities. You can listen back to the episode here: https://bit.ly/4gTwS9P

3 9

Reposted by ALK Positive Lung Cancer UK

Lung Foundation Australia @lungfoundation.bsky.social · 6d

✨ Brisbane was buzzing as the World Bronchiectasis Conference landed - and for the first time, consumers weren’t just attending, they were shaping the conversation. 💬

🎤 Real voices, real impact. Discover how our consumers helped shape the WBC experience: buff.ly/0bnr4sc

#WBC2025 #Bronchiectasis

Celebrating Consumer Voices at World Bronchiectasis Conference 2025

When the World Bronchiectasis Conference came to Brisbane in July, there was a palpable sense of excitement.

buff.ly

1 1

Reposted by ALK Positive Lung Cancer UK

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 4d

🤖 How can multimodal AI support #PrecisionOncology? At #ESMOAI25, the session “Multimodal AI for clinical decision support” will explore tumour boards, real-world data, explainability & integration challenges.

👉 www.esmo.org/meeting-cale...

#ESMOAI25 #DigitalOncology #HealthAI

2 3

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 5d

We’re in Belfast for BOPA 2025 (3-5 Oct).

Our treasurer, Geoff Otterman, is representing us & hosting our stand.

BOPA is a key oncology pharmacy event - it gives us the chance to:

▪️Highlight ALK+ #lungcancer
▪️Connect with the pharmacy community

If you’re at the conference come & say 👋 #LCSM

2

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 5d

More than 60K people in England miss out on radiotherapy each year. For #lungcancer, delays cost lives. Prof Pat Price calls it a “cancer care crisis.” ALK+ UK supports Radiotherapy UK & #CatchUpWithCancer in calling for urgent action in the National Cancer Plan. #LCSM

6

Reposted by ALK Positive Lung Cancer UK

Paul Belcher FRCP MFPH Hon 🇪🇺🇬🇧 @pauljbelcher.bsky.social · 6d

🪵 Affluent effluence: #AirPollution caused by indoor #WoodBurning in wealthier urban areas is increasingly linked to declining #Lung function

New findings presented at @europeanrespsoc.bsky.social congress suggest a rising #PublicHealth threat in Europe

www.emjreviews.com/respiratory/...

Indoor Wood Burning in Affluent Areas Problematic for Lung Health

Indoor wood burning is linked to declining lung function, with UK data showing rising emissions, increased use among older adults, and concerning health risks for vulnerable populations.

www.emjreviews.com

7 5

Reposted by ALK Positive Lung Cancer UK

BTOG @btog.bsky.social · 7d

"🧩 Local Consolidative Therapy – survival benefits or overtreatment?
Hear from experts tackling difficult questions in non-smoking lung cancer.
🎫 Register today
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
With @RuthStraussFdn"

1 2

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 6d

Scientists have found not all ALK+ #LungCancer fusions act the same.

Variant 3 can grow faster & may respond less well to some ALK drugs.

Knowing the exact fusion variant could help doctors plan more personalised treatment & improve outcomes. #LCSM

🔗 www.dkfz.de/en/news/pres...

Not all ALK fusions act the same: Variants influence treatment success in lung cancer

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...

www.dkfz.de

5

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 8d

What a weekend! 💙 Our 4th ALK+ #LungCancer UK National Conference brought together world-class experts & our amazing community.

From clinical trials & DVLA rules to brain imaging debates & personal stories - we covered so much.

Videos will be shared soon for anyone who couldn’t be there. #LCSM

9

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 9d

Read the manifesto 🔗 walescanceralliance.org/wp-content/u...

walescanceralliance.org

4

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 9d

As a member of @walescanceralliance.org, we are pleased to share the Alliance’s manifesto to improve cancer care in Wales.

Published today, this outlines 4 key recommendations, & we are calling on all parties to commit to delivering these should they form the next Welsh Government. #LCSM

1 1 5

Reposted by ALK Positive Lung Cancer UK

All You Need is Lungs @allyouneedislungs.bsky.social · 9d

Ruth Strauss Foundation have grants up to £50,000 available for research into Non-Smoking #LungCancer; to improve understanding, diagnosis & quality of life 🫁

🗓️ Apply by 10 Jan 2026 #LCSM

ruthstraussfoundation.com/grants-progr...

4 11

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 10d

We’ve launched our 2024 ALK+ #LungCancer UK Impact Report.

In 2024, we:
💙 Supported more than 750 members
💙 Reached millions our social media platforms
💙 Delivered the All You Need Is Lungs campaign (800K + impressions)
💙 Strengthened clinical guidance
💙 World-class satisfaction scores

#LCSM

5

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 10d

Lorlatinib is changing the outlook for ALK+ #lungcancer. New CROWN trial data shows a median PFS over 5 years in first-line treatment, with strong activity in the brain. A huge step forward, but side effects & sequencing still matter. #LCSM

🔗 www.cancernursingtoday.com/post/new-hor...

New Horizons in ALK+ NSCLC: Expanding Treatment Frontiers and Improving Survival | Cancer Nursing Today

Dr. Gadgeel highlighted results from the CROWN trial specifically, which evaluated the use of lorlatinib, a third-generation ALK inhibitor, in the first-line setting.

www.cancernursingtoday.com

4

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 11d

Big annnouncement today at our ALK+ UK National Conference: Lynsey Conway is our new Chief Executive 💙

With over 20 years in #lungcancer - including launching the @uklungcancer.bsky.social in Parliament - Lynsey brings deep experience and commitment to our ALK+ community.

#LCSM

5

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 11d

At #MLS_DC25 in Washington, a session on ALK TKIs showed how the field has moved from crizotinib in 2013 to ensartinib in 2025.

Choosing first-line therapy depends on efficacy, safety, and patient factors - there’s no one-size-fits-all in ALK+ #LungCancer

#LCSM

3

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 12d

@tnewsomdavis.bsky.social @prof-ali-g.bsky.social @btog.bsky.social

2